Exactly. There was so many posts about testing numbers it made me curious about what the relationship looked like. I wanted to see if there was an obvious rev bump but it’s not that simple.
If the pre-sales that deflated Q3 has been used it could a big quarter. There were 9.3M tests this half compared to 2.4M 2H20. That resulted in $7.7M for the half and last quarter we only did $2.4M.
The lack of guidance as they gave last year makes me think this is not as likely.
I’m happy though as this was just an (unfortunate) bonus for GSS and the big opportunity is in the protozoan and STI kits.
GSS is now worth $50m more (vs pre-covid) after proving its quality by shifting quickly to create covid test kits all whilst growing international relationships and sales, which is where the big money is.
Exactly. There was so many posts about testing numbers it made...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.0¢ |
Change
-0.005(0.70%) |
Mkt cap ! $152.8M | |||
| Open | High | Low | Value | Volume |
| 71.5¢ | 71.5¢ | 71.0¢ | $315.8K | 442.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 66386 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.5¢ | 12710 | 3 |
View Market Depth
| Last trade - 15.58pm 26/06/2024 (20 minute delay) ? |
| GSS (ASX) Chart |